Abstract Library

#2964 Personalized Therapy in a Case of Esophageal NEC Based on Tumor Genome Sequencing

Introduction: High-grade esophageal neuroendocrine carcinomas (NEC) constitute a rare subgroup of neuroendocrine neoplasms, with a particularly aggressive behaviour and unfavourable prognosis. To date, there are no validated biomarkers for personalized therapy and cytotoxic chemotherapy remains the standard of care. However, tumor genome sequencing may help improve NEC molecular landscape knowledge in order to identify novel targets for an individualized approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: La Salvia A

Authors: La Salvia A, Espinosa Olarte P, Modrego Sanchez A, Riesco Martinez M, Garcia Carbonero R,

Keywords: Esophageal neuroendocrine carcinoma, tumor genome sequencing, immunotherapy, tumor burden, personalized therapy,

#2239 pNET G3 Tumor Stabilization Achieved by an Individualized Molecular Therapy Based on Tumor Genome Sequencing Results

Introduction: High-grade pancreatic neuroendocrine neoplasms (pNENs) constitute a heterogeneous group of malignant neoplasms, encompassing neuroendocrine tumors (NET) G3 and carcinomas (NEC). Due to poor data on NET G3 tumors no standard therapy in metastatic disease could be established so far. Tumor genome sequencing might help to better profile NET G3 tumors and could provide novel opportunities for individualized and thereby successful patient specific treatments.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Steurer M

Authors: Steurer M, Lauer U, Hinterleitner C, Sipos B, la Fougère C,

Keywords: NET G3, tumor genome sequencing, individual therapy,